In episode 464, Mike and James and talk about 4 recent publications that should likely impact you practice if not today, then tomorrow. We talk about how long to give narcotics for acute MSK injuries, how to treat dyslipidemias, a non-steroid cream for psoriasis and a single dose of antibiotics for operative vaginal delivery.

Show notes 

In episode 463, James and Mike talk about the latest reports of the results of the 2 COVID-19 vaccine trials. We give you all the numbers you need to know and maybe more importantly we discuss the nuances around industry bias, the approval process and general thoughts around vaccines in these crazy times.

Show notes 

In episode 462, James and Mike invite Scott Garrison to talk about some important nuances around guideline recommendations and how low we should lower systolic blood pressure. We look in detail at the SPRINT trial and then come up with a reasonable (in our minds) approach to what thresholds we should use.

Show notes 

In episode 461, James and Mike invite Tina Korownyk to talk about the important question of whether or not virtual visits are as good as face-to-face when it comes to diagnosing undifferentiated presentations.

Show notes 

Tools for Practice

In episode 460, James and Mike invite Mike Kolber back again to answer the question does advising patients to abstain from alcohol reduce atrial fibrillation recurrence. The results may surprise you!

Show notes 

Tools for Practice

In episode 459, James and Mike invite Mike Kolber to talk about whether or not the increased rate of colorectal cancer in people under 50 means we should be screening earlier. We talk about all the numbers and put the risk into the context of the absolute numbers.

Show notes 

1) Tools for Practice

In episode 458, James and Mike finally get back to being PREMIUM and cover a number of new and useful RCTs. We discuss 4 new Vitamin D trials, atrial fibrillation and do you need both rate and rhythm control, swollen legs and cellulitis, and is colchicine the new statin. Check out the PREMIUM podcast for all the answers.

Show notes 

In episode 457, James and Mike yet again invite Joey Ton to go through the evidence around reaching a target serum urate level in patients with gout. As with many arbitrary thresholds determined from observational studies (sometimes), or just made up, when you properly study if there is a benefit to achieving these levels the theory really crumbles under the weight of the evidence.